Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation
- 1 November 2001
- journal article
- clinical trial
- Published by Elsevier BV in Transplantation Proceedings
- Vol. 33 (7-8), 3621-3623
- https://doi.org/10.1016/s0041-1345(01)02558-1
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- New Molecular Assays to Predict Occurrence of Cytomegalovirus Disease in Renal Transplant RecipientsThe Journal of Infectious Diseases, 2000
- CLINICAL UTILITY OF QUANTITATIVE CYTOMEGALOVIRUS VIRAL LOAD DETERMINATION FOR PREDICTING CYTOMEGALOVIRUS DISEASE IN LIVER TRANSPLANT RECIPIENTS1Transplantation, 1999
- Prophylaxis of cytomegalovirus infection in renal transplantation.Nephrology Dialysis Transplantation, 1998
- Clinical practice guidelinesJournal of the American Society of Nephrology, 1998
- CYTOMEGALOVIRUS PROPHYLAXIS WITH ANTIVIRAL AGENTS IN SOLID ORGAN TRANSPLANTATIONTransplantation, 1998
- COMPARATIVE STUDY OF CYTOMEGALOVIRUS (CMV) ANTIGENEMIA ASSAY, POLYMERASE CHAIN REACTION, SEROLOGY, AND SHELL VIAL ASSAY IN THE EARLY DIAGNOSIS AND MONITORING OF CMV INFECTION AFTER RENAL TRANSPLANTATION1Transplantation, 1997
- LONG-TERM PROGNOSIS OF RENAL TRANSPLANTATION AFTER PREEMPTIVE TREATMENT OF CYTOMEGALOVIRUS INFECTIONTransplantation, 1997
- Preemptive Ganciclovir Therapy To Prevent Cytomegalovirus Disease in Cytomegalovirus Antibody-Positive Renal Transplant RecipientsAnnals of Internal Medicine, 1995
- Ganciclovir pharmacokinetics during renal impairmentAntimicrobial Agents and Chemotherapy, 1988
- Clinical Pharmacokinetics of Ganciclovir in Patients with Normal and Impaired Renal FunctionClinical Infectious Diseases, 1988